Single Maximal Exercise Session and the Metabolic Response of Physically Inactive Young Adults (EASY-Study)
- Conditions
- Physical Deconditioning
- Registration Number
- NCT06680713
- Lead Sponsor
- Sergio Martinez-Huenchullan
- Brief Summary
The goal of this clinical trial is to learn how the metabolic parameters of physically inactive young adults respond to a progressive exercise testing. The main questions it aims to answer are:
Does a progressive exercise test induce metabolic adaptations that differ from a normal or physiologic status? Does the changes in circulating insulin might indicate metabolic dysfunctions in physically inactive young adults? Researchers will compare the metabolic status at baseline (rest) and the responses immediately after the finalization of a progressive exercise test until fatigue by collecting blood and urine samples before and after the exercise testing.
Participants will:
Undergo a progressive exercise test on a cycle ergometer where vital signs such as heart rate, blood pressure, rating of perceived effort, pulse and muscle oximetry will be recorded during the test.
Visit the laboratory once where all procedure will be conducted there. Stay in touch for the following week in case some exercise-related symptoms develops.
- Detailed Description
Design: This is a quasi-experimental study comparing pre-and post-intervention. The research question investigates the influence of changes in blood lactate influenced by exercise on the plasma concentration of FGF21 in physically inactive people. This project has the approval of the Scientific Ethics Committee of the Valdivia Health Service (Ord. 222/2022) and has Biosafety certification by the Institutional Biosafety Committee of the Austral University of Chile (No. 36/23).
Sample: People over 18 years of age (and up to 30 years of age) enrolled in the Physical Therapy program at the Austral University of Chile will be included. They must be physically inactive (perform less than 150 minutes/week of moderate physical activity and/or 75 minutes/week of vigorous physical activity) and without medical contraindications to perform physical activity. People who are taking medications that influence blood glucose or insulin levels and/or with anti-inflammatory effects will be excluded. The sample size calculation was performed considering the following parameters: a power of 95%, an alpha value of 0.05, a difference in pre- and post-intervention means of FGF21 of 50 pg/ml (100 vs 150 pg/ml), with a standard deviation for both groups of 50 pg/ml. With these data, the sample size is 16 participants, and considering a 20% drop-off, the final size is 20 participants, where recruitment will be by convenience and maintaining gender parity.
Variables: At the time of entering the study, the age years, and sex of the participants will be recorded. Anthropometric variables such as weight in kilograms and height in meters will be recorded using a scale (InBody® 270) and a height rod (SECA) respectively. From these measurements, the body mass index (BMI) will be calculated in kilograms/meters. For the calculations of the waist-hip ratio (WHR) and waist-height ratio (WHR), the waist circumference will be measured in centimeters using the navel area as a reference point. The hip circumference will be measured as the largest circumference obtained at the trochanteric femoral level. The levels of total and segmental muscle and fat mass will be measured using the InBody® 270 bioimpedance meter. The level of spontaneous physical activity will be measured using the International Physical Activity Questionnaire (IPAQ) in its short version. To induce elevations in blood lactate, an incremental load test will be applied on a cycle ergometer or stationary bicycle, in which the pedaling load will be increased by 30W every 3 minutes, starting from an initial load of 30W until reaching the point of fatigue. Before starting the test, participants will remain seated for 10 minutes, during which time heart rate, subjective sense of exertion (SSE) with the modified Borg Scale, blood pressure, pulse oximetry, and muscle (vastus lateralis of quadriceps) will be recorded at rest. In addition, a venous blood sample will be taken in a 2 ml tube with EDTA and another tube without anticoagulant for the subsequent plasma measurement of FGF21 with a specific ELISA kit for this (RayBio® catalog ELH-FGF21) and complementary biochemical tests (glycemia, insulinemia, total cholesterol, triglycerides, HDL, LDL, VLDL, non-HDL cholesterol, transaminases (GOT and GPT), creatinine, uric acid, urea and urea nitrogen). In addition, lactate measurement will be performed from a digital prick with a sterile lancet. For this, a specific reactive strip will be used, which will be measured with the AccuTrend Plus ® device. In parallel, the participant will be asked to bring a urine sample from the same day on an empty stomach for biochemical analysis (proteinuria, creatinuria, albuminuria, glucosuria). Once these measurements have been taken at rest, the incremental stress test will begin. Thus, on a cycle ergometer, each participant will begin the test with a pedaling cadence of 60-70 RPM at 30W load. Every 3 minutes this load will increase by 30W, always maintaining the same pedaling cadence. During the execution of the test, participants will always be supervised and guided by a professional physical therapist. Heart rate, pulse and muscle oximetry, and SSE will be assessed minute by minute, while blood pressure will be measured every 3 minutes. At the end of the test, the test execution time, the distance traveled in meters, heart rate, blood pressure, SSE, and final pulse and muscle oximetry will be recorded. The percentage of frequency reserve used during the test will be calculated with the Karvonen formula, which depends on the heart rates at rest and post-test. Fatigue at the end of the test will be understood as the fulfillment of one or more of the following criteria: use of heart rate reserve ≥ 90%, subjective feeling of effort ≥ 18/20 according to the original Borg scale, blood pressure ≥ 200/100 mg of Hg, the desire of the participant to finish the test (Figure 3).
Immediately after the test, a new venous blood sample will be taken in a 2 ml EDTA tube and another tube without anticoagulant. In addition, the post-exercise blood lactate concentration will be measured by finger prick using a specific reagent strip and with the AccuTrend Plus ® device. In addition, a post-exercise urine sample will be requested for the biochemical analysis previously described. Subsequently, the participant's vital signs will be monitored for 10 minutes after the test to ensure proper recovery.
It is reiterated that, as an assessment of potential confounding/intermediate variables, the following biochemical parameters will be measured from blood samples taken pre- and post-exercise: Total cholesterol, triglycerides, HDL, LDL, VLDL, non-HDL cholesterol, insulin, glucose, and transaminases (GOT, GPT), creatinine, uric acid, urea, and urea nitrogen. While, for urine samples, the levels of proteinuria, albuminuria, creatinuria, and glucose will be assessed.
Statistical analysis
Quantitative variables will be expressed as median and interquartile range, while qualitative variables will be described in terms of absolute frequencies. To calculate potential differences between pre-and post-stress test values, particularly lactate and FGF21, as well as transaminase levels and kidney function markers, the Wilcoxon test or Student t-test for related samples will be used, depending on how the data distribution behaves (normal or nonparametric). In addition, associations between lactate and FGF21 concentrations, both pre-and post-exercise, will be explored using the Spearman correlation index and bivariate regression models. In addition, other potential associations of interest will be explored using the Spearman correlation index. For all analyses, a p-value equal to or less than 0.05 will be considered statistically significant, using SPSS version 20 and GraphPad version 8 software.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
- Physically inactive (less than 150 minutes of weekly moderate-intensity or less than 75 minutes of weekly vigorous physical activity.
Without medical contraindication to perform physical activity
- Consumption of drugs with anti-inflammatory and/or hypoglycemic effects during the last two weeks.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Glycemia Up to 2 months Glucose in mg/dl
Insulinemia Up to 2 months Insulin in uUI/ml
- Secondary Outcome Measures
Name Time Method Total cholesterol Up to 2 months Total cholesterol in mg/dl
HDL cholesterol Up to 2 months HDL cholesterol in mg/dl
LDL cholesterol Up to 2 months LDL cholesterol in mg/dl
VLDL cholesterol Up to 2 months VLDL cholesterol in mg/dl
Triglycerides Up to 2 months Triglycerides in mg/dl
GOT (transaminase) Up to 2 months GOT in U/L
GPT (transaminase) Up to 2 months GPT in U/L
Proteinuria Up to 2 months Proteinuria in mg/dl
Creatinine clearance Up to 2 months Creatinine clearance in g/L
Albuminuria Up to 2 months Albuminuria in mg/L
Glucosuria Up to 2 months Glucosuria in mg/dl
Trial Locations
- Locations (1)
Universidad San Sebastián
🇨🇱Valdivia, Los Rios, Chile